Filing Flows › Interpace Biosciences (IDXG) › Free cash flow
Interpace Biosciences (IDXG) free cash flow by quarter
Interpace Biosciences' free cash flow was $41K in Q2 2026 (second quarter 2026), -71% from Q1 2026. Over the last 5 quarters it ranged from $41K (Q2 2026) to $2.1M (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $41K | -71% | — |
| Q1 2026 | $142K | -93% | — |
| Q4 2025 | $2.1M | +15% | +99% |
| Q3 2025 | $1.8M | +73% | — |
| Q4 2024 | $1.1M | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' free cash flow?
Interpace Biosciences' free cash flow was $41K in Q2 2026 (second quarter 2026), -71% from Q1 2026.
How has Interpace Biosciences' free cash flow changed?
Over the last 5 quarters it ranged from $41K (Q2 2026) to $2.1M (Q4 2025).